arrow
G

Giancarlo Bisagni

azienda usl-irccs
H指数:35
被引数:5,652

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial☆

肿瘤浸润淋巴细胞与BMI在早期HER2阳性乳腺癌中的相互作用:ShortHER试验分析☆

2025-10-100
OAAI
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

A-BRAVE试验:一项使用抗PD-L1药物avelumab治疗高风险三阴性早期乳腺癌患者的III期随机试验

2025-08-280
OAAI
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
2025-04-080
OAAI
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

绝经前激素受体阳性早期乳腺癌患者的辅助内分泌治疗选择: 来自前瞻性GIM23-POSTER研究的见解

BREAST
IF7.9
2024-10-011
OAAI
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024-08-012
OAAI
Impact of Body Mass Index (BMI) on the efficacy of different adjuvant chemotherapy schedules in patients with breast cancer: analysis from the randomized phase III GIM2 trial
2024-05-020
PRE
Deciphering the immune molecular signature associated with pembrolizumab efficacy in the neoadjuvant setting of Triple-Negative Breast Cancer patients: a single-centre experience

解读与pembrolizumab在三阴性乳腺癌患者新辅助治疗中的疗效相关的免疫分子特征: 单中心经验

2024-05-020
PRE
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials
2024-04-011
OAAI
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo trials (MIG)
2024-03-010
PRE
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
2023-09-071
OAAI
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

根据晚期乳腺癌国际共识指南的内分泌耐药/敏感性分类的预后和临床影响: 来自Mammella InterGruppo (MIG) 和Gruppo Italiano Mammella (GIM) 研究的个体患者水平分析

2023-05-017
OAAI
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2-early breast cancer: a correlative analysis of two phase II trials
2023-03-010
PRE
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts
2023-03-010
PRE